37 One of the major challenges in cardiovascular disease is the identification of reliable clinical 38 biomarkers which can be measured routinely in plasma. MicroRNAs were recently 39 discovered to circulate in the bloodstream in a remarkably stable form. Because of their 40 stability and often tissueand disease-specific expression, and the possibility to measure 41 them with high sensitivity a...

objective: to ascertain the effects of soy [in the forms of textured soy protein (tsp) and soy-nut] on lipid profiles, apolipoproteins, inflammatory and prothrombotic markers and blood pressure in elderly women with the metabolic syndrome. materials and methods: the study is a 12-week parallel randomized controlled trial that was conducted in rural health centres of babol, iran. the participant...

STUDY OBJECTIVES To evaluate the implication of plasma biomarkers to future cardiovascular events in nondiabetic patients with stable coronary artery disease (CAD). Designs and settings: Prospective, follow-up study at a tertiary referral center. Patients and measurement: Serial plasma biomarkers including high-sensitivity C-reactive protein (hsCRP), homocysteine, soluble adhesion molecules, vo...

Background: The frequency of laughter has been associated with cardiovascular disease and related biomarkers, but no previous studies have examined association between changes in blood pressure levels. We sought to identify temporal relationships daily life systolic diastolic participants from 2010 through 2014.

To the Editor: Wang et al. (Dec. 21 issue)1 suggest that novel biomarkers in aggregate have little influence on the prediction of first cardiovascular events or death. We wonder whether there were sufficient analyses to warrant this conclusion. As described, there were only 68 “major” cardiovascular events in women and 101 in men. In the crucial multimarker analyses, a quarter of these events w...

BACKGROUND We examined several novel biomarkers of different pathophysiologic pathways as predictors of cardiovascular mortality in participants enrolled in the Minnesota Heart Survey (MHS), a population-based study of cardiovascular disease (CVD) risk factors. METHODS In a nested case-control study within MHS, 7 biomarkers were assayed in serum samples from 211 patients identified after 8-15...

The early identification of susceptibility to adverse cardiovascular outcomes and risk stratification amongst asymptomatic individuals, as well as amongst those with overt disease continues to be one of the major priorities of clinically-orientated research in the field of atherothrombosis (Dotsenko et al., 2008). Conventional cardiovascular risk assessment is based on traditional risk factors ...

Cardiovascular disease (CVD) is the major cause of death in patients with advanced chronic kidney disease (CKD). Recent studies have suggested that novel risk factors, uremia- or dialysis-related, are of great importance, as they act synergistically with the highly prevalent traditional risk factors for CVD in CKD patients. Whereas an ideal single biomarker, i.e., one that adds relevant prognos...

PURPOSE We have previously demonstrated associations between the urinary proteome profile and coronary artery disease (CAD) in cross-sectional studies. Here, we evaluate the potential of a urinary proteomic panel as a predictor of CAD in the hypertensive atherosclerotic cardiovascular disease (HACVD) substudy population of the Anglo-Scandinavian Cardiac Outcomes Trial study. EXPERIMENTAL DESI...

Bortezomib is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Traditionally, bortezomib was thought to have little cardiovascular toxicity; however, there is increasing evidence that bortezomib can lead to cardiac complications including left ventricular dysfunction and atrioventricular block. We present the case of a 66-year-old man with multiple myeloma and per...